通用名称

avatrombopag

儿科标签批准日期

2019/3/21 0:00:00

特定指示/秒

Juvenile animal toxicity study

标签更改摘要

- Safety and effectiveness in pediatric patients have not been established. - In a 10-week juvenile toxicology study in rats, avatrombopag was administered at doses ranging from 20 to 300 mg/kg/day. There were no test article-related mortality or clinical signs at doses up to 300 mg/kg/day. In the stomach, dose-dependent degeneration, regenerative hyperplasia, and atrophy of the glandular epithelium occurred at 100 and 300 mg/kg/day; exposures at 100 mg/kg/day in male rats were 14-times the AUC in patients at the recommended dose of 60 mg once daily. An increased incidence of background focal mineralization was also observed in the kidneys of females at 300 mg/kg/day (female rat exposure was 50-times the human exposure based on AUC at the 60 mg daily dose). - Postmarketing study

治疗类别

N/A

立法类型

PREA Only

产品说明书链接

书号

N/A

研究年龄

N/A

学习类型

N/A

研究设计

N/A

登记的患者

N/A

患者分析

N/A

中心的数量

N/A

国家数量

N/A

西班牙裔拉美裔/拉丁裔总计

N/A

非西班牙裔/非拉丁裔总人数

N/A

总数#种族不明

N/A

亚裔学生总数

N/A

黑人总数

N/A

白人总数

N/A

夏威夷或太平洋岛民总数

N/A

美洲印第安人/阿拉斯加本地人总数

N/A

其他种族总计

N/A

未知种族总数

N/A

国家

N/A